Company: SRPT
Filing Date: 2025-04-24
Form Type: DEF 14A
Source: 0000950170-25-058003
Chunk: 54

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-04-24
Form: DEF 14A
Chunk 54
---
, state and local tax compliance and consultation services. All other fees are fees related to subscription to KPMG LLP’s Accounting Research Online and Custom Learning Portal. Policy on Audit Committe e Pre-Approval of Fees The audit committee must pre-approve all services to be performed for us by KPMG LLP. Pre-approval is granted usually at regularly scheduled meetings of the audit committee. If unanticipated items arise between regularly scheduled meetings of the audit committee, the audit committee has delegated authority to the chairwoman of the audit committee to pre-approve services, in which case the chairwoman communicates such pre-approval to the full audit committee at its next meeting. The audit committee also may approve the additional unanticipated services by either convening a special meeting or acting by unanimous written consent. During 2024 and 2023, all services provided by KPMG LLP were pre-approved by the audit committee in accordance with this policy. Vote Required and Bo ard Recommendation The affirmative vote of a majority of the votes cast is required to approve this proposal, excluding abstentions and broker non-votes. The Board recommends that stockholders vote “FOR” ratification of this appointment. THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK.

<div align='center'>31</div>

STOCK OWNED BY SAREPTA THERAPEUTICS, INC . MANAGEMENT AND PRINCIPAL STOCKHOLDERS The following table sets forth certain information regarding the ownership of our common stock as of April 8, 2025, with respect to: (i) each person known by us to beneficially own more than 5% of the outstanding shares of our common stock, (ii) each of our directors, (iii) each of our named executive officers and (iv) all directors and executive officers as a group.

| Name and Address of Beneficial Owner(1)                                                    |     | Amount and       
 Nature of        
 Beneficial       
 Ownership        
 (

# of Shares)(2) |            |     | Percent of 
 Class(2)   |      |   |
| Officers and Directors                                                                     |     |                  |            |     |            |      |   |
| Richard J. Barry(3)                                                                        |     |                  |  3,233,787 |     |            |  3.3 | % |
| M. Kathleen Behrens, Ph.D.(4)                                                              |     |                  |    253,192 |     | *          |      |   |
| Hans Wig